Brief: Seastar Medical Announces Completion Of FDA Enrollment Requirement For Save Surveillance Registry Evaluating Quelimmune Safety For Pediatric Aki
05/03/2026 13:24
March 5 (Reuters) - SeaStar Medical Holding Corp ICU.O: SEASTAR MEDICAL ANNOUNCES COMPLETION OF FDA ENROLLMENT REQUIREMENT FOR SAVE SURVEILLANCE REGISTRY EVALUATING QUELIMMUNE SAFETY FOR PEDIATRIC AKI Source text: ID:nGNX3RQzrM Further company coverage: ICU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview